As of 2025-11-27, the EV/EBITDA ratio of Fulcrum Therapeutics Inc (FULC) is -8.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FULC's latest enterprise value is 429.89 mil USD. FULC's TTM EBITDA according to its financial statements is -52.05 mil USD. Dividing these 2 quantities gives us the above FULC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.7x - 11.4x | 8.6x |
| Forward P/E multiples | 13.5x - 19.3x | 15.8x |
| Fair Price | (15.51) - (12.94) | (13.95) |
| Upside | -237.0% - -214.3% | -223.3% |
| Date | EV/EBITDA |
| 2025-11-26 | -8.14 |
| 2025-11-25 | -8.44 |
| 2025-11-24 | -8.60 |
| 2025-11-21 | -8.24 |
| 2025-11-20 | -8.05 |
| 2025-11-19 | -8.41 |
| 2025-11-18 | -6.97 |
| 2025-11-17 | -6.91 |
| 2025-11-14 | -6.10 |
| 2025-11-13 | -6.21 |
| 2025-11-12 | -5.86 |
| 2025-11-11 | -5.69 |
| 2025-11-10 | -5.30 |
| 2025-11-07 | -5.27 |
| 2025-11-06 | -5.29 |
| 2025-11-05 | -5.47 |
| 2025-11-04 | -5.87 |
| 2025-11-03 | -6.40 |
| 2025-10-31 | -6.18 |
| 2025-10-30 | -6.06 |
| 2025-10-29 | -6.67 |
| 2025-10-28 | -7.19 |
| 2025-10-27 | -6.91 |
| 2025-10-24 | -6.56 |
| 2025-10-23 | -6.34 |
| 2025-10-22 | -6.41 |
| 2025-10-21 | -6.95 |
| 2025-10-20 | -6.56 |
| 2025-10-17 | -6.37 |
| 2025-10-16 | -6.62 |
| 2025-10-15 | -6.90 |
| 2025-10-14 | -6.13 |
| 2025-10-13 | -6.18 |
| 2025-10-10 | -6.37 |
| 2025-10-09 | -6.88 |
| 2025-10-08 | -6.89 |
| 2025-10-07 | -6.58 |
| 2025-10-06 | -6.79 |
| 2025-10-03 | -6.56 |
| 2025-10-02 | -6.79 |
| 2025-10-01 | -6.65 |
| 2025-09-30 | -6.54 |
| 2025-09-29 | -6.11 |
| 2025-09-26 | -6.25 |
| 2025-09-25 | -5.98 |
| 2025-09-24 | -5.77 |
| 2025-09-23 | -5.05 |
| 2025-09-22 | -5.13 |
| 2025-09-19 | -5.08 |
| 2025-09-18 | -5.20 |